Company intelligence
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Verified activity
Signals from Oxford BioTherapeutics
2 published signals
Partnerships
Oxford BioTherapeutics notes that GSK agreed to pay up to $1.295B to Hutchmed for ex-Greater China rights to HMPL-A830, a preclinical KRAS-EGFR conjugate, which Hutchmed calls an Antibody-Targeted Therapy Conjugate (ATTC), with Phase 1 planned to start H2 2026.
Reported by Harald Haeske
Capital & Finance
Oxford BioTherapeutics notes that a new ADC-like class using a KRAS inhibitor as payload has been priced by GSK at $110M upfront while still being in preclinical stage.
Reported by Harald Haeske